Skip to main content
Hit enter to search or ESC to close
Close Search
Menu
Company
Team
Psybrary™
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact
twitter
facebook
linkedin
Investors
Media Coverage
NASDAQ: ENVB
Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Media Coverage
The Future of Psychedelics: Why Next-Generation Molecules Will Win [Microdose]
March 31, 2025
Enveric Biosciences’ Patent For Non-Hallucinogenic Psychedelic Compounds [Microdose]
February 26, 2025
EXCLUSIVE: Non-Hallucinogenic Psychedelic Compounds Show Promise For Treating Addiction And ADHD [Benzinga]
February 25, 2025
A New Horizon in Joint Disease Treatment: Enveric Biosciences and Restoration Biologics Forge Licensing Agreements [Microdose]
February 4, 2025
Enveric Biosciences Inks Two Licensing Agreements With Restoration Biologics To Treat Joint Disease [Benzinga]
February 4, 2025
Enveric Biosciences Receives Two US Patents for Psilocybin Derivatives [Microdose]
December 3, 2024
Enveric Biosciences Advances Non-Hallucinogenic DMT Analog Drug With Promising Preclinical Results [Benzinga]
November 25, 2024
Enveric inks $62M licensing deal for psilocin prodrug [Green Market Report]
November 12, 2024
Enveric Biosciences Out-Licenses Key Program To MycoMedica In $62M Deal [Benzinga]
November 12, 2024
Enveric Biosciences Expands Mental Health Patent Portfolio With 5 New Additions [Benzinga]
November 4, 2024
1
2
3
…
13
›
Close Menu
Company
Team
Psybrary™
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact
twitter
facebook
linkedin
